New melphalan combo shows promise in Half-Matched transplants for blood cancer patients
NCT ID NCT03159702
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approach is safe and helps patients live longer without their cancer getting worse. Results showed the treatment was generally safe, with serious side effects monitored, and one-year progression-free survival was evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact